CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Habil Khorakiwala

Cofounder, Wockhardt

Search every verified Habil Khorakiwala interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In an August 13, 2026, interview, Wockhardt founder and chairman Habil Khorakiwala discussed the company's recent financial performance and growth outlook. He attributed a 26% year-on-year revenue increase and a swing to positive EBITDA of 107 crore rupees to consistent performance across recent quarters. Khorakiwala stated that the company's margins are expected to improve year on year, with significant improvement anticipated after fiscal year 2029, and projected that fiscal year 2028 would mark the beginning of rapid growth, followed by a "hockey stick" growth trajectory from fiscal year 2029 onward. Regarding the company's pipeline, Khorakiwala noted that the antibiotic Zynetic is expected to enter phase two and phase three clinical trials, with a commercial launch planned for the US and India. He described peak sales targets for Zynetic of $1.5 to $2 billion as achievable during the patent life, possibly earlier, while adding that actual results might exceed current perceptions. He also mentioned plans for a global scientific and medical academy aimed at sharing experiences with doctors to build credibility for India as a scientific organization, with India serving as the initial model for this initiative.

Recent appearances

Verified interview transcripts

Notable quotes

“When we talk of a peak sale, it always means getting it in the life of patent. So, we can It is quite possible that we reach the this peak sale little earlier also. But definitely during the life of patent, that would be the our peak sale as far as Zynetic is concerned. It may be we might do better actually than the feeling and perception as we are getting.”

“Definitely '28 FY '28 we would be see beginning of a rapid growth. And '29 onwards, you will see our growth like a hockey stick.”

“We are the only company talking about it everybody is opposing. See the point is in 80s I fought not to have it. Okay. Today world is different. India has not progressed in 40 years. That's the way you have to look at it for tomorrow. If you want to create a culture of innovation and all those things.”

“We want to maintain leadership in antibiotic space for all time to come because you could get in a lifetime rare opportunity where you are today ahead of everybody in molecule and research. Now to maintain that is very important but our long-term strategy is very different business model which I'm not sharing to anybody. Our business model do not get expire at the when that product expires. We will compete even when ”

“It will cost between $10,000. Per day cost will be about $1,200 to $1,500. Treatment cost will be about 10,000 to 12,000 $15,000 depending on treatment. In the US correct and in India that will be significantly lower, right? It will be about 25% of that cost. 20 25%.”

“We estimate the peak sale of this drug would be what $1.5 to 2 billion peak sales which will be maybe in 3 4 5 years mostly peak say four five six yeah maybe more but total market size is 9 billion rupees so a 20% market share there is reasonable.”

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →